A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation

Completed

Conditions: Hodgkin Disease
Lymphoma, Large-cell, Anaplastic

Registration Number: NCT03942263

Lead Sponsor: Takeda

Brief Summary: The purpose of this study is to describe patterns of treatment used for cHL and sALCL in real world setting.

Detailed Description: This is a non-interventional, prospective and retrospective study of participants with cHL and sALCL. The study will collect information on therapy and outcome of cHL and sALCL in real-life clinical practice.

The study will enroll approximately 2000 participants. Based on the diagnosis of the disease, participants will be assigned to one of the following groups:

* Newly Diagnosed and RR cHL Participants

* Newly Diagnosed and RR sALCL Participants

This multi-center trial will be conducted in Russia. The retrospective data will be collected for the participants with RR cHL or RR sALCL at the time of enrollment and for participants with RR cHL or RR sALCL within 3 years prior to inclusion in the study at Visit 1 (Baseline). The prospective data will be collected for a period of 2 years from Visit 1 (Baseline) to Visit 5 (Month 24, Final Visit), both for newly diagnosed participants with cHL or sALCL and participants with RR cHL or RR sALCL at the time of enrolment, and participants with RR cHL or RR sALCL within 3 years prior to inclusion in the study.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 2000

Inclusion Criteria

Male and female participants 18 years or older by the time of enrollment.
Histologically confirmed diagnosis of cHL or sALCL.
Newly diagnosed participants, or participants with RR cHL or RR sALCL at the time of enrollment, or participants with RR cHL or RR sALCL within 3 years prior to inclusion in the Study.

Exclusion Criteria

Unconfirmed diagnosis of cHL or sALCL.
Current, previous (within the last 3 years) or planned (for the next 2 years) participation in interventional clinical trials.
Participation in the non-interventional study CHL-5001 "An international, multi-centre, non-interventional retrospective study to describe treatment pathways, outcomes, and resource use in participants with classical Hodgkin lymphoma (B-HOLISTIC)" (Sponsor is Takeda Pharmaceuticals International AG).
Participants for whom the minimum study dataset was not available from their hospital medical records.

Study Type: OBSERVATIONAL

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Description of Treatment Patterns Used for cHL or sALCL	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Percentage of Participants Receiving Various Chemotherapy Regimens	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Percentage of Participants who Were Eligible for AutoSCT did not Receive it (Including Reasons)	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Distribution of Pre-SCT Therapy Regimens	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Distribution of Relapse/Refractory (RR) Treatment Patterns	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Percentage of Participants who Received Chemotherapy Regimens as per National Guidelines	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Percentage of Participants who Received Radiotherapy Including Site (Extended/Involved) and Total Dosing	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Percentage of Participants who Received Autologous Stem Cell Transplantation (AutoSCT)	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Percentage of Participants who Received Allogeneic Stem Cell Transplantation (AlloSCT)	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Distribution of First Line Treatment Patterns According to Prognostic Group	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)

Secondary Outcome Measures

Name	Time	Method
Disease Free Survival-1 (DSF1)	From date of complete remission after first line of therapy up to relapse or till the latest date of participant observed (up to Month 24)	DFS1 is defined as the time from the date of complete remission after first line of therapy till relapse or till the latest date of participant observed.
Overall Survival (OS)	From the date of cHL or sALCL diagnosis confirmation until the date of death from any cause or till the latest date of participant observed (up to Month 24)	OS is defined as the time passed from the date of cHL or sALCL diagnosis confirmation until the date of death from any cause or till the latest date of participant observed.
Freedom From Treatment Failure-1 (FFTF1)	From date of initiation first therapy until any treatment failures such as disease progression, not achieving complete remission after therapy, relapse, discontinuation of therapy for complications, death from any cause or till observed (up to Month 24)	FFTF1 is defined as the time passed from date of initiation first therapy until any treatment failures such as disease progression, do not achieving complete remission after therapy, relapse, discontinuation of therapy for complications, death from any cause or till the latest date of participant observed.
Percentage of Participants with Complete Remission (CR) Achieved by the end of Treatment Regimen	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	CR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 is defined as complete disappearance of all target lesions and all nodes with long axis less than (\<) 10 millimeter (mm).
Percentage of Participants With Partial Remission (PR) Achieved by the end of Treatment Regimen	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	PR based on RECIST 1.1 is defined as greater than or equal to (\>=) 30 percent (%) decrease in the sum of longest diameters (SLD) of target lesions but not a CR. CR is defined as complete disappearance of all target lesions and all nodes with long axis \<10 mm.
Event Free Survival-1 (EFS1)	From date of initiation first therapy until therapy discontinuation, not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till observed (up to Month 24)	EFS-1 is defined as the time passed from date of initiation first line therapy until any events such as discontinuation of therapy for any reasons, do not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till the latest date of participant observed.
Percentage of Participants With Progression Disease (PD) While on the Treatment	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	PD based on RECIST 1.1 is defined as \>20% increase in the SLD of target lesions. For small lymph nodes measuring \<15 mm post therapy, a minimum absolute increase of 5 mm and the long diameter should exceed 15 mm.
Percentage of Participants With Relapse (Both Early [<12 Months After the end of First Line Treatment] and Late Relapses)	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Percentage of Participants With Primary Resistance	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Percentage of Participants With Overall Response Achieved by the end of Treatment Regimen	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	Overall response based on RECIST 1.1 is defined as the percentage of participants who have a PR or CR to therapy; it does not include stable disease and is a direct measure of drug tumoricidal activity. PR is defined as \>=30% decrease in the SLD of target lesions but not a CR. CR is defined as complete disappearance of all target lesions and all nodes with long axis \<10 mm.
Percentage of Participants With Stable Disease (SD) Achieved by the end of Treatment Regimen	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	SD based on RECIST 1.1 is defined as changes in the SLD of targeted lesions ranging between reduction of \<10% to an increase by \<20% without the appearance of a new lesion, and irrespective of positron emission tomography (PET) results.
Percentage of Resistant Participants to the Second and Later Treatment Lines	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Percentage of Participants in Whom Brentuximab Vedotin was Used	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Distribution of Treatment Patterns Containing Brentuximab Vedotin in Clinical Practice	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Disease Free Survival (DFS) After the Treatment Line Including Brentuximab Vedotin Based on the Number of Cycles of Brentuximab Vedotin Performed Within this Treatment Line	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	DFS will be assessed after the treatment line including brentuximab vedotin based on the number of cycles of brentuximab vedotin performed within this Treatment Line. DFS is defined as the time from the date of complete remission till relapse or till the latest date of participant observed.
Percentage of Participants With CR Achieved to the end of the Given Treatment Regimen Based on the Number of the Cycles of Brentuximab Vedotin Performed Within This Treatment Line	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	CR based on RECIST 1.1 is defined as complete disappearance of all target lesions and all nodes with long axis \<10 mm.
Distribution of Clinical Variables for cHL and sALCL at the Time of Resistance/Relapses	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	Clinical variable will include stage, histological types, immunohistochemistry data (yes/no) and ALK-status (negative/positive).
Percentage of Participants for Whom PET and PET/Computed Tomography (CT) was Used for Primary Disease Diagnostic and Staging	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Percentage of Participants for Whom PET and PET/CT Scan was Used for Interim Treatment Response Evaluation	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
OS Based on use of PET/CT Scan for Initial Disease Staging, Interim and Final Response Assessment During Frontline and Second Line Treatment	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	OS is defined as the time passed from the date of initiation of cHL or sALCL treatment until the date of death from any cause or till the latest date of participant observed. OS will be analyzed by Cox regression.
Timepoint of Performing Interim Response Evaluation With PET/CT Scan (Number of Cycle After Which the Evaluation is Performed, Time From the Start of Last Cycle of Therapy)	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	Timepoints will include number of cycle after which the evaluation is performed and time from the start of last cycle of therapy.
FFTF Based on the Number of Cycles of Brentuximab Vedotin Performed Within the Treatment Line	From initiation therapy date until any treatment failures such as disease progression, not achieving complete remission after therapy, relapse, discontinuation of therapy for complication, death from any cause, or till observed (up to Month 24)	FFTF will be assessed based on the number of cycles of brentuximab vedotin performed within this treatment line. FFTF is defined as the time passed from date of initiation therapy until any treatment failures such as disease progression, do not achieving complete remission after therapy, relapse, discontinuation of therapy for complications, death from any cause or till the latest date of participant observed.
EFS Based on the Number of Cycles of Brentuximab Vedotin Performed Within this Treatment Line	From initiation therapy date until therapy discontinuation, not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till observed (up to Month 24)	EFS will be assessed based on the number cycles of brentuximab vedotin performed within this treatment line. EFS is defined as the time passed from date of initiation therapy until any events such as discontinuation of therapy for any reasons, do not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till the latest date of participant observed.
Percentage of Participants With Overall Response Achieved to the end of the Given Treatment Regimen Based on the Number of the Cycles of Brentuximab Vedotin Performed Within This Treatment Line	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	Overall response is defined as the percentage of participants who have a partial or complete response to therapy; it does not include stable disease and is a direct measure of drug tumoricidal activity. PR is defined as \>=30 % decrease in the SLD of target lesions but not a CR. CR is defined as complete disappearance of all target lesions and all nodes with long axis \<10 mm.
Distribution of Clinical Variables for cHL and sALCL at the Time of Primary Diagnosis	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	Clinical variable will include stage, histological types, immunohistochemistry data (yes/no), ALK-status (negative/positive), prognostic groups, prognostic risk factors (International Prognostic Score (IPS), International Prognostic Index, Age-adjusted International Prognostic Index, International T-cell Lymphoma Project Score, Prognostic Index for peripheral T-cell lymphoma unspecified \[PTCL-U\] \[PIT\]), prognostic risk factors, and risk factors for relapse.
Distribution of Imaging Patterns Used for Disease Control of the Participants Being in Remission	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Event Free Survival-2 (EFS2)	From date of initiation second therapy until therapy discontinuation, not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till observed (up to Month 24)	EFS-2 is defined as the time passed from date of initiation second line therapy until any events such as discontinuation of therapy for any reasons, do not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till the latest date of participant observed.
Percentage of Participants With Progressive Disease Developed While on the Treatment Regimen Including Brentuximab Vedotin Achieved Based on the Number of the Cycles of Brentuximab Vedotin Performed Within This Treatment Line	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	PD based on RECIST 1.1 is defined as \>20% increase in the SLD of target lesions. For small lymph nodes measuring \<15 mm post therapy, a minimum absolute increase of 5 mm and the long diameter should exceed 15 mm.
Number of Cycles of Brentuximab Vedotin Before and After Stem Cell Transplantation (SCT)	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Percentage of Participants for Whom PET and PET/CT Scan Were Used to Evaluate Final Treatment Response	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Timepoint of Performing Final Response Evaluation With PET/CT scan (Number of Cycle After Which the Evaluation is Performed, Time From the Start of Last Cycle of Therapy)	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	Timepoints will include number of cycle after which the evaluation is performed and time from the start of last cycle of therapy.
Time of Performing PET and PET/CT Scan After SCT	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Distribution of Imaging Patterns Used for Primary Disease Diagnostic and Staging in Different Regions of Russia	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Percentage of cHL or sALCL Participants who Used Healthcare Resources: Hospitalizations, Sick Leave Sheet	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)	Healthcare resources will include hospitalizations and sick leave sheet.
Distribution of Imaging Patterns Used for Treatment Response Evaluation	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Number of Hospitalizations	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Number of Days Spent on Hospital Beds	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Number of Sick Leaves	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Number of Days Spent on Sick Leaves	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Disease Free Survival-2 (DSF2)	From date of complete remission after second line of therapy up to relapse or till the latest date of participant observed (up to Month 24)	DFS2 is defined as the time from the date of complete remission after second line of therapy till relapse or till the latest date of participant observed.
Freedom From Treatment Failure-2 (FFTF2)	From date of initiation second therapy until any treatment failures such as disease progression, not achieving complete remission after therapy, relapse, discontinuation of therapy for complications, death from any cause or till observed (up to Month 24)	FFTF2 is defined as the time passed from date of initiation second line therapy until any treatment failures such as disease progression, do not achieving complete remission after therapy, relapse, discontinuation of therapy for complications, death from any cause or till the latest date of participant observed.
Number of Cycles of Brentuximub Vedotin Administered in Routine Clinical Practice	From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)

Trial Locations

Locations (50): State Budget Public Health Institution "Regional Oncological Dispensary"
🇷🇺
Irkutsk, Russian Federation
The State Budgetary Institution of Healthcare "Regional Oncologic Dispensary"
🇷🇺
Penza, Russian Federation
Kaluga Regional Clinical Oncologic Dispensary
🇷🇺
Kaluga, Russian Federation
Regional State Budgetary Institution of Health "Kostroma Oncological Dispensary"
🇷🇺
Kostroma, Russian Federation
Public health institution Lipetsk Regional Oncology Center
🇷🇺
Lipetsk, Russian Federation
State budgetary health care institution "Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine"
🇷🇺
Chelyabinsk, Russian Federation
Regional State Budgetary Institution of Healthcare Krasnoyarsk Regional Clinical Oncologic Dispensary named after A.I. Kryzhanovsky"
🇷🇺
Krasnoyarsk, Russian Federation
State budgetary institution of health care of the Nizhny Novgorod region "Regional Clinical Hospital named after NA Semashko"
🇷🇺
Nizhny Novgorod, Russian Federation
State Budgetary Institution of Healthcare Leningrad Regional Clinical Hospital
🇷🇺
Saint-Petersburg, Russian Federation
Tatarstan Regional Clinical Cancer Center
🇷🇺
Kazan, Russian Federation
State budgetary health care institution "Regional Oncology Center 2"
🇷🇺
Magnitogorsk, Russian Federation
Federal State Budgetary Institution "National Medical-Surgical Center named after N.I. Pirogov" Ministry of Health of the Russian Federation
🇷🇺
Moscow, Russian Federation
Federal State Institution National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation
🇷🇺
Moscow, Russian Federation
State Budgetary Institution of Healthcare of the Novosibirsk Region "City Clinical Hospital No. 2"
🇷🇺
Novosibirsk, Russian Federation
Federal State Budgetary Institution of Public Health of the Novosibirsk Region "Research Institute of Fundamental and Clinical Immunology"
🇷🇺
Novosibirsk, Russian Federation
State Budgetary Institution of Healthcare of the Republic of Karelia Republican Hospital named after V. A. Baranova "
🇷🇺
Petrozavodsk, Russian Federation
State Budgetary Institution of Healthcare of the Novosibirsk Region "State Novosibirsk Regional Clinical Hospital"
🇷🇺
Novosibirsk, Russian Federation
Medical Radiological Research Center. A.F. Tsyba - a branch of the Federal State Budgetary Institution "Scientific Medical Research Center of Radiology" of the Ministry of Health of the Russian Federation
🇷🇺
Obninsk, Russian Federation
Budget institution of healthcare of Omsk region "Clinical Oncologic dispensary"
🇷🇺
Omsk, Russian Federation
State budgetary institution of public health "Orenburg regional clinical hospital 1"
🇷🇺
Orenburg, Russian Federation
State Budgetary Institution of Healthcare "Pskov Regional Clinical Oncologic Dispensary"
🇷🇺
Pskov, Russian Federation
Federal State Budgetary Educational Institution of Higher Education Rostov State Medical University of the Ministry of Health of the Russian Federation
🇷🇺
Rostov-on-Don, Russian Federation
Federal State Budgetary Educational Institution of Higher Education "North-Western State Medical University named after II Mechnikov" of the Ministry of Health of the Russian Federation
🇷🇺
Saint-Petersburg, Russian Federation
Federal State Budgetary Institution "N. N. Petrov National Medical Research Center of Oncology" of the Ministry of Health of Russia
🇷🇺
Saint-Petersburg, Russian Federation
Federal State Budgetary Institution "Russian Research Institute of Hematology and Transfusiology of the Federal Medical and Biological Agency"
🇷🇺
Saint-Petersburg, Russian Federation
Study State Budgetary Institution of Health "Oncology Dispensary No. 2" of the Ministry of Health of the Krasnodar Territory
🇷🇺
Sochi, Russian Federation
State Budgetary Institution of Healthcare of the Stavropol Territory "Stavropol Regional Clinical Oncology Dispensary"
🇷🇺
Stavropol, Russian Federation
Budgetary institution of the Khanty-Mansiysk Autonomous Okrug Ugra
🇷🇺
Surgut, Russian Federation
State Healthcare Institution of Tula Region "Tula Regional Clinical Hospital"
🇷🇺
Tula, Russian Federation
State institution of the Komi Republic "Komi Republican Oncological Dispensary"
🇷🇺
Syktyvkar, Russian Federation
State autonomous health care institution of the Tyumen region "Multidisciplinary clinical medical center "Medical City"
🇷🇺
Tyumen, Russian Federation
Ministry of Health of the Republic of Bashkortostan State Autonomous Healthcare Institution Republican Clinical Oncologic Dispensary
🇷🇺
Ufa, Russian Federation
State Healthcare Institution "Regional Clinical Oncologic Dispensary"
🇷🇺
Ulyanovsk, Russian Federation
State budgetary health care institution "Volgograd Regional Clinical Oncology Center"
🇷🇺
Volgograd, Russian Federation
Budget institution of health care of the Vologda region "Vologda regional clinical hospital"
🇷🇺
Vologda, Russian Federation
State budgetary institution of health care of the Yaroslavl region "Regional Clinical Hospital"
🇷🇺
Yaroslavl, Russian Federation
State budgetary healthcare institution of the Astrakhan region Alexander-Mariinsky regional clinical hospital
🇷🇺
Astrakhan, Russian Federation
Autonomous Institution "Republican Clinical Oncology Dispensary" of the Ministry of Health of Chuvashia
🇷🇺
Cheboksary, Russian Federation
State budgetary institution of health care of the Kemerovo region "Regional Clinical Oncology Center"
🇷🇺
Kemerovo, Russian Federation
Regional State Budgetary Institution of Health "Regional Clinical Hospital 1" named after Professor S.I. Sergeeva, Ministry of Health of the Khabarovsk Territory
🇷🇺
Khabarovsk, Russian Federation
Federal State Budgetary Institution "Main Military Clinical Hospital named after Academician N.N.Burdenko" of the Ministry of Defense of the Russian Federation
🇷🇺
Moscow, Russian Federation
Federal State Budgetary Institution of Science "Kirov Research Institute of Hematology and Blood Transfusion of the Federal Medical and Biological Agency"
🇷🇺
Kirov, Russian Federation
Regional State Budgetary Institution of Health "Regional Clinical Hospital"
🇷🇺
Krasnoyarsk, Russian Federation
Federal State Budgetary Institution "National Medical Research Center of Oncology named after N.N. Blokhina "of the Ministry of Health of the Russian Federation
🇷🇺
Moscow, Russian Federation
State Budgetary Healthcare Facility of Nizhny Novgorod Region "City Clinical Hospital 12"
🇷🇺
Nizhny Novgorod, Russian Federation
Federal State Budgetary Educational Institution of Higher Education Ryazan State Medical University named after Academician I.P. Pavlova" of the Ministry of Health of the Russian Federation
🇷🇺
Ryazan, Russian Federation
Saratov State Medical University named after V.I.Razumovsky of the Ministry of Health of Russia "Clinic of Physiopathology and Hematology named after Professor V.Ya. Shustov"
🇷🇺
Saratov, Russian Federation
State Budgetary Institution of Healthcare of the Moscow Region Moscow Regional Research Clinical Institute named after M.F. Vladimirskoye
🇷🇺
Moscow, Russian Federation
The Moscow State Clinical Hospital No. 52 of the Moscow City Department of Healthcare, State Budgetary Institution of Health Care
🇷🇺
Moscow, Russian Federation
Moscow City Hematology Center on the basis of the State Budgetary Institution of Healthcare of the City of Moscow City Clinical Hospital named after S.P. Botkin Moscow Department of Health
🇷🇺
Moscow, Russian Federation

A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts